Pluri Inc.
Develops cell therapies from placental cells for inflammatory & hematologic disorders.
PLUR | NDAQ
Overview
Corporate Details
- ISIN(s):
- US72940R3003
- LEI:
- Country:
- United States of America
- Address:
- MATAM ADVANCED TECHNOLOGY PARK, 0 HAIFA
- Website:
- https://pluri-biotech.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Pluri Inc., formerly Pluristem Therapeutics, is a biotechnology company specializing in the research, development, and manufacturing of cell-based products and therapeutics. The company leverages proprietary 3D cell-expansion technology platforms to create solutions from human placental cells. Pluri aims to improve human well-being and sustainability by developing therapies for various conditions, including ischemic, inflammatory, and hematologic disorders. It collaborates with research partners and academic institutions to advance its cell-based product pipeline for commercial use.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pluri Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pluri Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
